Overview
Acadia Pharmaceuticals is a biopharmaceutical company commercializing Nuplazid (pimavanserin), the first FDA-approved drug specifically for hallucinations and delusions associated with Parkinson's disease psychosis. They are also developing treatments for Alzheimer's disease psychosis and Rett syndrome.
More in Neuropharmaceuticals
Latest industry news
NIH-Backed Device Gives People With Paralysis a New Path to Communication
2026-10-14 · Research
ABILITY Neurotech Begins Clinical Testing of Its Brain-Computer Interface System
2026-10-13 · Research
Flourish Emerges From Stealth With Bezos and Google Ventures Backing to Decode the Nervous System
2026-10-12 · Funding
Cala Health Launches Next-Generation TAPS Therapy Wearable Nationwide for Tremor and Parkinson's Patients
2026-10-11 · Product
Company details
Category
💊 Neuropharmaceuticals
Location
San Diego, USA
Funding
Public · NASDAQ: ACAD
Website
www.acadia-pharm.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →